Analysts’ Weekly Ratings Changes for Revvity (RVTY)

Revvity (NYSE: RVTY) has recently received a number of price target changes and ratings updates:

• 9/9/2026 – Revvity is now covered by UBS Group AG. They set a “neutral” rating and a $140.00 price target on the stock.
• 9/4/2026 – Revvity had its price target raised by KeyCorp from $125.00 to $165.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Revvity is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $135.00 price target on the stock.
• 9/1/2026 – Revvity is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $135.00 price target on the stock.
• 8/16/2026 – Revvity was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/8/2026 – Revvity was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/5/2026 – Revvity had its “outperform” rating reaffirmed by Evercore Inc.
• 8/4/2026 – Revvity was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/30/2026 – Revvity was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is currently 13.33%.

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.